Poly (ADP-Ribose) polymerase inhibitors: Recent advances and future development

Clare L. Scott, Elizabeth M. Swisher, Scott H. Kaufmann

Research output: Contribution to journalReview articlepeer-review

225 Scopus citations


Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.

Original languageEnglish (US)
Pages (from-to)1397-1406
Number of pages10
JournalJournal of Clinical Oncology
Issue number12
StatePublished - Apr 20 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Poly (ADP-Ribose) polymerase inhibitors: Recent advances and future development'. Together they form a unique fingerprint.

Cite this